Nemaura Medical to Present at the LD Micro Virtual Invitational Conference on June 9, 2021
Nemaura Medical (NASDAQ: NMRD) will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10, 2021. CEO Faz Chowdhury, Ph.D., is scheduled to present on June 9 at 1:00 PM ET, Track 3. Investors can register to watch the presentation here. Nemaura specializes in non-invasive wearable devices for diabetes management, including the CE mark approved sugarBEAT® and the AI-enhanced proBEAT™.
- None.
- None.
Loughborough, England, June 01, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that Chief Executive Officer Faz Chowdhury, Ph.D. will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021.
Dr. Chowdhury will deliver his corporate presentation on June 9 at 1:00pm ET, Track 3.
Investors can register to watch the presentation here.
Investors interested in scheduling a meeting with management should contact assistant@ldmicro.com.
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly
For more information, please visit www.NemauraMedical.com.
Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
FAQ
What is Nemaura Medical's presentation schedule for the LD Micro Virtual Conference?
Where can investors register to watch Nemaura Medical's presentation?